Inhibikase Therapeutics, Inc. (IKT)

Inhibikase Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr 20, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Market Cap	308	270	225	8	13	37
Market Cap Growth	57.21%	19.76%	2769.29%	-38.01%	-65.73%	-46.68%
Enterprise Value	129.7	91.2	127.88	-4.92	-10.17	-3.52
Last Close Price	1.81	2.05	3.25	1.27	3.00	8.82
PE Ratio	-	-4.18	-2.80	-0.40	-0.70	-1.81
PS Ratio	-	-	-	30.16	102.66	11.93
PB Ratio	1.78	1.56	2.38	0.72	0.60	0.96
P/TBV Ratio	1.03	1.17	0.81	0.70	0.60	0.70
P/FCF Ratio	-	-9.71	-11.77	-0.43	-0.72	-2.59
P/OCF Ratio	-	-9.72	-11.77	-0.43	-0.73	-2.59
EV/Sales Ratio	-	-	-	-18.90	-82.40	-1.14
EV/EBITDA Ratio	-	-1.76	-4.48	0.25	0.56	0.24
EV/EBIT Ratio	-	-1.75	-4.47	0.25	0.56	0.24
EV/FCF Ratio	-	-3.28	-6.68	0.27	0.58	0.25
Debt / Equity Ratio	-	0	0	0.04	0.01	0.01
Debt / EBITDA Ratio	-	-	0.00	-0.03	-0.02	-0.02
Debt / FCF Ratio	-	-	-0.01	-0.03	-0.02	-0.02
Net Debt / Equity Ratio	-1.03	-1.03	-1.03	-1.15	-1.08	-1.05
Net Debt / EBITDA Ratio	3.44	3.44	3.41	0.63	1.25	2.74
Net Debt / FCF Ratio	6.43	6.43	5.09	0.70	1.29	2.83
Asset Turnover	-	0	0	0.01	0.00	0.11
Quick Ratio	21.54	21.54	26.13	3.85	6.25	10.08
Current Ratio	21.70	21.70	26.37	4.13	6.59	10.47
Return on Equity (ROE)	-36.05%	-36.05%	-52.00%	-118.88%	-60.74%	-61.35%
Return on Assets (ROA)	-37.15%	-37.15%	-50.55%	-101.87%	-53.79%	-51.58%
Return on Invested Capital (ROIC)	1937.32%	1937.32%	1355.30%	1211.83%	967.08%	818.05%
Return on Capital Employed (ROCE)	-38.82%	-38.82%	-53.98%	-124.36%	-60.78%	-60.92%
Earnings Yield	-15.64%	-23.90%	-35.69%	-248.82%	-142.67%	-55.10%
FCF Yield	-9.01%	-10.30%	-8.49%	-230.37%	-138.84%	-38.66%
Buyback Yield / Dilution	-314.60%	-314.60%	-293.35%	-42.74%	-39.15%	-121.72%
Total Shareholder Return	-314.60%	-314.60%	-293.35%	-42.74%	-39.15%	-121.72%

Updated Mar 26, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q